While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The price you pay for Beyfortus may depend on factors such as your child’s dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Beyfortus.

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...

He emphasized strong product launches, including Beyfortus reaching blockbuster status in its first year and ALTUVIIIO set to ...

Newer drugs like Beyfortus and Altuviiio show strong growth, offsetting challenges from biosimilars and generic competition. Sanofi faces near-term profitability pressure due to increased R&D ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...